<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Schizophrenia in adults: Guidelines for prescribing clozapine</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Schizophrenia in adults: Guidelines for prescribing clozapine</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Schizophrenia in adults: Guidelines for prescribing clozapine</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Oliver Freudenreich, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph McEvoy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H20931793"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> has been found to be an effective treatment in persons with schizophrenia resistant to treatment with other antipsychotic drugs. In addition, clozapine is an effective treatment for schizophrenia accompanied by persistent suicidal or self-injurious behavior. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a>’s unique side effect profile, which includes a low rate of life-threatening agranulocytosis, gives rise to numerous considerations in prescribing, monitoring, and side effect management in the use of the drug.</p><p>This topic describes <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>’s indications/contraindications, pharmacology, adverse effects, and administration in schizophrenia or schizoaffective disorder. The efficacy of clozapine in schizophrenia is discussed separately. Clozapine is compared with other antipsychotic drugs separately. (See  <a class="medical medical_review" href="/z/d/html/14808.html" rel="external">"Evaluation and management of treatment-resistant schizophrenia", section on 'Clozapine'</a> and  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p class="headingAnchor" id="H20931856"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Primary indications for <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in patients with schizophrenia or schizoaffective disorder are schizophrenia symptoms partially or fully resistant to treatment with other antipsychotic drugs, or accompanied by persistent suicidal or self-injurious behavior. Other clinical indications in schizophrenia patients include sensitivity to extrapyramidal symptoms and patients with tardive dyskinesia. (See  <a class="medical medical_review" href="/z/d/html/14808.html" rel="external">"Evaluation and management of treatment-resistant schizophrenia", section on 'Clozapine'</a>.)</p><p class="headingAnchor" id="H692269627"><span class="h1">CONTRAINDICATIONS AND PRECAUTIONS</span></p><p class="headingAnchor" id="H3542143012"><span class="h2">Neutropenia</span><span class="headingEndMark"> — </span>Potentially life-threatening agranulocytosis led to restrictions on <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>’s use in many countries, but neutrophil monitoring has allowed for safer use of the medication. The US Food and Drug Administration requires patients in the United States to have a minimum absolute neutrophil count (ANC) greater than or equal to 1500/microL to initiate clozapine [<a href="#rid1">1</a>]. An exception is made for patients with Duffy-null associated neutrophil count (DANC) who are subject to a lower ANC level. (See <a class="local">'Duffy-null associated neutrophil count (DANC)'</a> below.)</p><p>A history of clozapine-induced severe neutropenia or agranulocytosis (ANC below 500/microL) is a relative contraindication for restarting <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>. Because the adverse effects and benefits of the drug vary widely among patients, the risks, benefits, and alternatives need to be weighed for each patient, and clozapine can be restarted if the harm from not using clozapine greatly outweighs the potential risks. Clozapine should be used with extreme caution when restarted. Many patients will quickly develop agranulocytosis again, but they cannot be identified in advance through testing. In a study of 53 patients who had experienced leukopenia or neutropenia from clozapine, 20 patients developed another blood dyscrasia that was more severe and occurred more rapidly upon rechallenge [<a href="#rid2">2</a>].</p><p>Continuing <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, as opposed to initiating, is subject to further restrictions in the United States based on ANC monitoring, described below. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H3455575970"><span class="h3">Duffy-null associated neutrophil count (DANC)</span><span class="headingEndMark"> — </span>Lower neutrophil thresholds were established for starting and treating <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in patients with confirmed DANC, a cause of neutropenia not associated with recurrent or severe infection that is most often seen in individuals of African descent and Sephardic Jews [<a href="#rid3">3</a>]. Treatment can be instituted and continued in patients with an ANC of at least 1000/microL. Collaboration with hematology is recommended to manage moderate or severe neutropenia in this patient group. (See  <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Normal variants &lt;1500/microL'</a>.)</p><p class="headingAnchor" id="H1327562953"><span class="h2">Cardiac disease</span><span class="headingEndMark"> — </span>In patients with risk factors for cardiovascular disease, a more complete baseline cardiovascular evaluation (including baseline echocardiogram) may be useful. The prevalence of asymptomatic left ventricular dysfunction is approximately 3 to 5 percent in adults 50 to 70 years old, and is higher among men, older patients, and patients with coronary disease.</p><p>Patients with a history of clozapine-induced myocarditis should only be rechallenged if the harm from not using <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> greatly outweighs the potential risks. Individuals with preexisting heart disease are at greater risk of morbidity from clozapine-induced myocarditis or the effects of orthostatic hypotension; they have less cardiac reserve should any, even temporary, cardiac damage and malfunction occur during the initiation of clozapine. When a rechallenge is considered after an episode of myocarditis due to clozapine or clozapine is used in individuals with preexisting heart disease, clozapine should be initiated in the inpatient setting with close monitoring of cardiac function. (See <a class="local">'Cardiovascular'</a> below and <a class="local">'Myocarditis/cardiomyopathy'</a> below.)</p><p class="headingAnchor" id="H2515637650"><span class="h2">Seizures</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> is relatively contraindicated in patients with a history of seizure, to be used only if the harm from not using clozapine greatly outweighs the potential risks. Individuals with a seizure disorder should have their seizures optimally controlled before clozapine is started. Patients with an elevated seizure risk, including those with an alcohol use disorder or a history of febrile seizures or epilepsy, should be considered for prophylactic treatment with an anticonvulsant medication when clozapine is initiated. They should be observed carefully as clozapine is initiated, using a conservative titration schedule and therapeutic drug monitoring to avoid excessive clozapine blood levels. A follow-up electroencephalogram may be indicated after clozapine treatment is established, and adjustment of anticonvulsant treatment may be necessary. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H1404562173"><span class="h2">Other conditions</span><span class="headingEndMark"> — </span>The metabolic effects of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> should be taken into account when weighing the risks and benefits from clozapine. Individuals with obesity, diabetes mellitus, dyslipidemias, or atherosclerotic cardiovascular disease may have worsening of these conditions when treated with clozapine, and more aggressive treatment of these disorders will be required.</p><p class="headingAnchor" id="H207140"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span>The pharmacologic mechanisms underlying <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>’s superiority for treatment-resistant schizophrenia are not known.</p><p class="headingAnchor" id="H207147"><span class="h2">Pharmacodynamics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> binds loosely and transiently to dopamine D2 receptors. Clozapine does not induce catalepsy or inhibit apomorphine-induced stereotypy in animal models as is seen with conventional antipsychotic medications; this may explain its reduced potential for producing movement abnormalities relative to tightly binding dopamine D2 antagonists such as <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>. Clozapine also binds to D1, D3, and D5 receptors, and has a high affinity for the D4 receptor, but the implications of these binding activities are unclear.</p><p><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> also interacts at histamine H1, acetylcholine muscarinic M1 and serotonin 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors, and at alpha-1-adrenoceptors. Postural dizziness, sedation, and increased appetite may reflect actions of clozapine at alpha-1, H1, and 5-HT2c receptors, respectively. Actions at the 5-HT2A and M1 receptors may reduce movement side effects [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H207154"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> is well absorbed. First-pass metabolism reduces its bioavailability to 60 to 70 percent of the administered dose; food has little effect on the bioavailability of clozapine. The elimination half-life of clozapine averages approximately 14 hours under steady state conditions, but there is substantial variability across individuals [<a href="#rid5">5</a>].</p><p><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> is extensively metabolized by the cytochrome P450 system in the liver, and excreted in both the urine and feces. Cytochrome P450 1A2 is primarily responsible for clozapine metabolism; cytochromes 2C19, 2C9, 2D6, and 3A4 play less important roles. Agents that induce cytochrome CYP1A2, such as tobacco cigarette smoke, will increase the metabolism of clozapine. Tobacco smokers may require twice the dose of nonsmokers to achieve similar blood levels. Strong inducers of CYP3A4 (eg, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>) will also reduce serum concentrations of clozapine; additive bone marrow toxicity with carbamazepine has been described [<a href="#rid6">6-10</a>]. Agents that inhibit CYP1A2 (eg, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a>) will decrease the metabolism of clozapine and may produce clinical toxicity at usual doses [<a href="#rid11">11</a>]. Cytochrome-related problems can be avoided by monitoring clozapine plasma levels while gradually increasing clozapine from a low starting dose. (See <a class="local">'Dose titration and plasma levels'</a> below.)</p><p>In addition, patients prescribed <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> should have their medication regimen analyzed for drug interactions when initiating and adjusting therapy; this may be done by use of the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p>The major metabolite of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, norclozapine (desmethylclozapine), has failed to demonstrate any therapeutic activity in clinical trials. Clozapine and norclozapine plasma levels are both reported by clinical labs, but only the clozapine level is useful for dose optimization [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3799781774"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H662821133"><span class="h2">Pretreatment assessment</span><span class="headingEndMark"> — </span>Assessment prior to treatment with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> should include evaluation of the patient’s general and cardiovascular health status. Other components of an evaluation include documentation and testing of:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count that includes an absolute neutrophil count (ANC). The minimum ANC required to initiate <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> is described above [<a href="#rid3">3</a>]. (See <a class="local">'Neutropenia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight and height (body mass index), waist circumference, fasting blood sugar (or HbA1c), and fasting lipids. (See <a class="local">'Weight gain'</a> below and <a class="local">'Insulin resistance and diabetes mellitus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug levels for patients on anticonvulsant medications (need to be in the therapeutic range). (See <a class="local">'Seizures'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vital signs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An Abnormal Involuntary Movement Scale documenting absence or presence of abnormal motor movements  (<a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">form 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in women of childbearing age.</p><p></p><p>In addition, consider obtaining measures of inflammation (eg, C-reactive protein) and cardiac muscle damage (eg, troponin levels). (See <a class="local">'Cardiovascular'</a> below.)</p><p class="headingAnchor" id="H528606618"><span class="h2">Dose titration and plasma levels</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Starting dose and titration</strong> – For patients initially starting <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in nonurgent situations, we prefer a slow titration. As an example, we suggest 12.5 to 25 mg once daily at bedtime for three to four days, then 25 to 50 mg once daily at bedtime for three to four days. We then increase further by 25 mg twice weekly. An initial test dose of 12.5 mg is recommended to confirm tolerability in patients who have never received clozapine.</p><p></p><p class="bulletIndent1">In urgent situations (active aggression/violence or self-injury/suicide) we double the titration rate above. For example, we suggest 50 mg once daily for three or four days, then 100 mg once daily for three to four days followed by increases of 50 mg twice weekly. Sleepiness is the primary clinical ceiling side effect, so as <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> dose is increasing, we simultaneously taper off other sedating agents. We monitor for seizure risk by asking patients or their families to report myoclonic jerking movements.</p><p></p><p>We adjust dosing for individuals of Asian descent as they require less <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> to reach therapeutic blood levels.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial target dose</strong> – The initial target dose for healthy, young adults is 300 mg/day. Older adult patients and patients with cardiac disease may need a lower target dose and a slower titration, particularly if they experience sedation or orthostatic hypotension to avoid falls or worsening cardiac function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Target plasma levels</strong> – Plasma levels can be checked after the initial target dose is reached or earlier (eg, after reaching 100 mg). A <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> plasma level in the range of 250 to 350 ng/mL is a reasonable target for a patient with schizophrenia. However, patients show great variation in both their symptomatic response and side effects and the target plasma level should be individualized based on these outcomes [<a href="#rid13">13</a>]. Once the therapeutic plasma level is reached, the patient’s clinical response should be monitored for two weeks before considering any further dose increase. For those who have refractory symptoms, it is reasonable to target levels higher than 350 ng/mL, despite there being limited evidence to suggest greater efficacy. In our experience, some patients can benefit from higher levels, and this approach is consistent with recommendations from the Treatment Resistance in Psychosis Working Group [<a href="#rid14">14</a>]. Side effects such as sleepiness and electroencephalogram slowing increase as clozapine blood levels increase [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">Plasma levels should be checked in the morning, ideally 8 to 10 hours following the previous evening dose. Given the pharmacokinetics of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, differences of a few hours in the time of evening dosing or morning plasma sampling will lead to large differences in reported plasma levels.</p><p></p><p class="headingAnchor" id="H87048126"><span class="h2">Maintenance dosing</span><span class="headingEndMark"> — </span>A maintenance dose of 300 to 600 mg/day is usually required for efficacy. The average final daily dose in patients with treatment-resistant psychosis is approximately 400 mg daily. Doses higher than 900 mg/day are not recommended.</p><p>Due to great interindividual variability in <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> metabolism, in rare instances, levels can reach toxic range with lower doses (eg, 100 mg/day) or fail to achieve therapeutic levels at higher doses (eg, 600 to 900 mg/day). Checking plasma levels is thus important during the titration phase; however, once a target dose is achieved, ongoing plasma level monitoring is not routinely necessary. Regular therapeutic drug monitoring can help detect unsuspected adherence problems early enough to take counter measures. (See <a class="local">'Dose titration and plasma levels'</a> above.)</p><p>Once the patient is stabilized on an effective maintenance dose, all or most of the daily dose may be given at bedtime. This will aid patients in getting to sleep and avoiding daytime sedation. Adherence can be improved by taking the medication at the time of routine, consistent behaviors, such as breakfast or bedtime preparations, and by prescribing once or twice daily rather than more frequently. However, some patients require split doses to avoid bed wetting or morning grogginess.</p><p class="headingAnchor" id="H1322011532"><span class="h2">Re-initiation after interruption</span><span class="headingEndMark"> — </span>If <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> treatment is interrupted for two or more days, we start clozapine at 12.5 mg once or twice daily in order to assess tolerability and decrease the risk of severe cardiovascular effects including orthostatic hypotension, syncope, and cardiac arrest [<a href="#rid16">16</a>]. If well tolerated, however, the previous dose can be achieved more quickly compared with patients who are initially started on clozapine.</p><p class="headingAnchor" id="H521211297"><span class="h1">MONITORING</span></p><p class="headingAnchor" id="H2966456257"><span class="h2">Neutrophil count</span><span class="headingEndMark"> — </span>For all patients taking <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in the United States, the US Food and Drug Administration (FDA) requires regular monitoring and registry reporting of neutrophil counts [<a href="#rid1">1</a>]. This process has been successful in allowing safe use of clozapine while avoiding deaths due to clozapine-induced agranulocytosis [<a href="#rid17">17</a>]. Revisions to United States regulations in 2015 lowered certain absolute neutrophil count (ANC) thresholds, expanding the number of patients eligible to receive the medication, and permitted clinicians to override ANC-based treatment recommendations to continue or restart clozapine in patients for whom the benefits of clozapine clearly exceed the risk of agranulocytosis [<a href="#rid1">1</a>]. Six separate registries administered by clozapine manufacturers were replaced with a single registry (the Clozapine Risk Evaluation and Mitigation Strategy [REMS] Program, available at their <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.newclozapinerems.com%2Fhome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F2r5E6nbVyq0a4jh%2BfOqSKrUAqgyE%2BJpWUQI4VPVQk4g&amp;TOPIC_ID=14772" target="_blank">website</a>).</p><p>As part of REMS, clinicians need to be registered and demonstrate that they are competent to prescribe <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> (ie, review clozapine-related materials from the Clozapine REMS Program website and pass a knowledge test). Pharmacies also need to be certified if they dispense clozapine. In order to receive clozapine, a patient must be entered into this registry and undergo regular monitoring of ANC that continues as long as a patient receives clozapine (“No blood, no drug”). Routine neutrophil monitoring is performed at the following intervals:</p><p class="bulletIndent1"><span class="glyph">●</span>Weekly during the first six months of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> administration</p><p class="bulletIndent1"><span class="glyph">●</span>Every other week for the second six months</p><p class="bulletIndent1"><span class="glyph">●</span>Every four weeks after one year, for the duration of treatment</p><p></p><p>If neutropenia develops during treatment, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> would either need to be monitored more frequently, stopped temporarily, or discontinued, based on the severity of neutropenia [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild neutropenia (ANC: 1000 to 1499/microL) – Continue treatment but increase monitoring frequency to three times per week.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate neutropenia (ANC: 500 to 999/microL) – Interrupt <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> treatment, increase monitoring to daily until ANC is 1000/microL at which point clozapine can be reinstituted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe neutropenia/agranulocytosis (ANC: &lt;500/microL) – Discontinue <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>. Rechallenge should only occur if the benefits outweigh the risks, in consultation with hematology.</p><p></p><p>ANC-based guidelines for continuing <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> differ in patients with Duffy-null associated neutrophil count (DANC) in the United States. (See <a class="local">'Duffy-null associated neutrophil count (DANC)'</a> above.)</p><p>Hospice patients receiving <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> only require ANC monitoring at six-month intervals.</p><p>All initial reports of an ANC under 1500/microL should be confirmed with a repeat ANC within 24 hours.</p><p>Clinicians can override the registry rules for treatment interruption due to neutropenia and continue <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> treatment despite moderate or severe neutropenia if continuing clozapine is clinically justified (ie, the psychiatric benefit outweighs the medical risk). Clinicians can similarly decide to rechallenge a patient who developed severe neutropenia. (See <a class="local">'Contraindications and precautions'</a> above.)</p><p>If agranulocytosis occurs, <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">filgrastim</a> hastens the return to ANC counts [<a href="#rid18">18,19</a>], although it is not clear this alters infection rates or mortality.</p><p class="headingAnchor" id="H2512790731"><span class="h3">Required bloodwork and COVID-19</span><span class="headingEndMark"> — </span>Monitoring ANC is required for prescribing and dispensing <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>. However, the coronavirus 2019 (COVID-19) public health emergency has necessitated social isolation and staying at home, which poses problems for patients treated with this medication. Patients and clinicians need to decide whether the risks of infection outweigh the benefits of obtaining blood work according to the monitoring schedule mandated by the FDA.</p><p>On March 22, 2020, the FDA offered guidance regarding the COVID-19 public health emergency and access to medications that are subject to REMS-required testing [<a href="#rid20">20</a>]. The guidelines allow patients to receive <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in the absence of laboratory testing of ANC if there are compelling reasons not to complete the testing. Based upon the existing evidence with respect to clozapine and neutropenia, the FDA guidance, and an expert consensus statement [<a href="#rid21">21</a>], we suggest the following approach to using clozapine and monitoring ANC:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients treated with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, one may reasonably decide that obtaining mandated clozapine blood work (ANC monitoring) during the COVID-19 pandemic is impossible or entails unacceptably high risks for patients or others. As an example, patients may be in isolation or in quarantine, or at high risk for mortality if they get infected with COVID-19 while traveling to a clinic or laboratory for blood work.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One factor that determines whether it is acceptable to waive ANC testing is duration of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> treatment. As an example, it is reasonable to temporarily forego testing in patients who have received the drug for at least one year and have never had an ANC &lt;2000/microL (or &lt;1500/microL if there is a history of DANC). The rationale is that the risk of severe neutropenia after 12 months of clozapine treatment is very low. In a meta-analysis of seven studies that included more than 31,000 patients who were treated with clozapine and followed for up to two years, the cumulative incidence of severe neutropenia after 12 months of treatment declined to an almost negligible level of 0.3 to 0.4 cases per 100 person-years of exposure [<a href="#rid22">22</a>]. The peak incidence of severe neutropenia occurred at one month of exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians should decide whether to continue <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> treatment in the absence of scheduled ANC monitoring in collaboration with patients and family members (or legal guardian), explaining the risks and benefits of proceeding without ANC monitoring and the rational for of this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients without a current ANC, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> prescriptions should specify the appropriate number of pills. For many patients on long-term clozapine treatment, this may simply be an additional 30-day supply of clozapine, if an ANC can be obtained the next month. However, a 60- or 90-day supply may be prudent if patients remain at high risk due to the pandemic. For patients newly started on clozapine, we suggest dispensing only a one- or two-week supply during the first six months of treatment, in conjunction with weekly ANC monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who develop flu-like symptoms such as fever, cough, and sore throat during a period without ANC monitoring should obtain an ANC and an urgent assessment for clozapine-associated neutropenia, either in-person or by telehealth, depending upon local protocols. Symptoms should not simply be attributed to possible COVID-19.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with flu-like symptoms may develop <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> toxicity (eg, sedation, myoclonus, or seizures) that requires reducing the dose by up to one-half. The reason is that some acute systemic infections are associated with increased serum clozapine concentrations. In addition, patients with respiratory illnesses may cease smoking, which is also associated with increased serum concentrations.</p><p></p><p class="bulletIndent1">The reduced dose should continue until the fever has abated for three days, after which the dose is then increased stepwise back to the dose used prior to onset of flu-like symptoms. Serum <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> concentrations can help with the dose adjustments.</p><p></p><p class="headingAnchor" id="H1748312328"><span class="h2">Cardiovascular</span></p><p class="headingAnchor" id="H2946021906"><span class="h3">Myocarditis</span><span class="headingEndMark"> — </span>In rare cases, clozapine-induced myocarditis can progress rapidly into cardiomyopathy and congestive heart failure. (See <a class="local">'Myocarditis/cardiomyopathy'</a> below.)</p><p>All patients should be monitored closely for at least the initial four weeks of treatment. This should include assessment of symptoms concerning for myocarditis (eg, malaise, chest pain, shortness of breath), vital signs each visit, electrocardiogram (ECG) at baseline, and then weekly laboratory tests including:</p><p class="bulletIndent1"><span class="glyph">●</span>Sedimentation rate or C-reactive protein</p><p class="bulletIndent1"><span class="glyph">●</span>Troponins</p><p></p><p>A significant increase in C-reactive protein (over 100 mg/L) and troponin elevation (greater than twice the upper limit of normal) have been reported to be 100 percent sensitive in detecting clozapine-induced myocarditis in symptomatic patients [<a href="#rid23">23</a>]. The eosinophil count often rises as well but less reliably and delayed.</p><p>In patients with suspected myocarditis or cardiomyopathy, echocardiography is a key imaging test to assess ventricular function and valve function. (See  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H3322755874"><span class="h3">QTc prolongation</span><span class="headingEndMark"> — </span>Due to its propensity to cause a dose-dependent QTc prolongation, we try to obtain an ECG prior to starting <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> for all patients, regardless of cardiovascular risk. A repeat ECG may be desirable once steady state is obtained.</p><p>The formula that most ECG machines use to calculate the corrected QT interval (Bazett formula) may overestimate it in patients with tachycardia. We typically seek consultation with a cardiologist in patients who develop tachycardia and a QTc &gt;500 msec while on <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>. Some of these patients may have a lower QTc and be able to safely continue the medication.</p><p class="headingAnchor" id="H3092029490"><span class="h2">Metabolic</span><span class="headingEndMark"> — </span>In order to detect treatment-emergent hyperglycemia and prevent diabetic ketoacidosis, fasting plasma glucose monitoring should be considered monthly at the beginning of treatment. Obtaining fasting glucose, however, can be difficult in outpatient settings; rising triglycerides may be a better indicator of developing insulin resistance. (See <a class="local">'Insulin resistance and diabetes mellitus'</a> below.)</p><p class="headingAnchor" id="H2329542531"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>Gastrointestinal hypomotility, which can result in an adynamic ileus, requires close clinical attention [<a href="#rid24">24</a>]. In patients who cannot reliably identify bowel problems, a preventive laxative (stool softener) is often prescribed when starting <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>. (See <a class="local">'Gastrointestinal hypomotility'</a> below.)</p><p class="headingAnchor" id="H41032386"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H1885516639"><span class="h2">Neutropenia/agranulocytosis</span><span class="headingEndMark"> — </span>Clozapine-induced agranulocytosis was estimated to occur at a rate of approximately 0.8 percent in a study of 12,760 patients receiving the medication; leukopenia occurred in almost 3 percent of cases [<a href="#rid25">25</a>]. The peak risks for both occurred early in treatment, between 6 to 18 weeks from initiation. Advancing age was a risk factor for agranulocytosis in this cohort. Regular blood monitoring over a five-year period has been estimated to reduce the risk of agranulocytosis from approximately 1 to 2 percent to 0.38 percent [<a href="#rid26">26</a>]. Neutrophil-monitoring during <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> treatment is discussed above. (See <a class="local">'Monitoring'</a> above.)</p><p class="headingAnchor" id="H2828470380"><span class="h2">Myocarditis/cardiomyopathy</span><span class="headingEndMark"> — </span>Studies have estimated the risk of clozapine-induced myocarditis to be 1 in 500 to 1 in 10,000 [<a href="#rid27">27</a>]. The true risk is likely closer to the 1 in 500 rate, as often only a minority of adverse medication-related events are diagnosed and reported. Early myocarditis is more common than later development of cardiomyopathy; cardiomyopathy may be accompanied by mitral regurgitation [<a href="#rid28">28</a>].</p><p>Most cases of myocarditis occur early in the course of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> treatment. The condition was detected within 16 days (median) of initiating clozapine in a study of 116 cases [<a href="#rid27">27</a>]. Approximately 80 percent of cases of clozapine-induced myocarditis occur within four weeks of drug initiation, and 90 percent occur within eight weeks.</p><p>Postmortem examination has most commonly revealed damaged myocytes and eosinophilic infiltration suggesting a type I Ig E-mediated acute hypersensitivity reaction. The time of onset of clozapine-induced myocarditis and the pathological findings support this hypothesis. Other contributing mechanisms may include cytokine release and high levels of catecholamines.</p><p>A typical pattern of nonspecific clinical symptoms (fever, tachycardia) and laboratory findings (elevated eosinophil count, sedimentation rate or c-reactive protein, troponins, creatine phospho-kinase, and brain natriuretic peptide), combined with a high index of suspicion for myocarditis (nonspecific symptoms, including malaise, as well as more alarming symptoms like chest pain or shortness of breath) in a patient started on <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> within the past four to eight weeks is needed to diagnose myocarditis in a clozapine patient. Some patients will have a mild and temporary increases in inflammatory markers and eosinophils at the beginning of treatment without progression to myocarditis.</p><p>In patients with suspected myocarditis or cardiomyopathy, echocardiography is a key imaging test to assess ventricular function and valve function. (See  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a>.)</p><p>A diagnosis of myocarditis should be followed by prompt discontinuation of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> and medical follow-up with the patient’s primary care clinician for supportive treatment. This course will usually lead to spontaneous resolution. Subsequent use of clozapine in cases with clear clozapine-induced myocarditis leads to recurrence of myocarditis in most cases when the drug is restarted.</p><p>Use of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in patients with preexisting heart disease and monitoring of patients at the initiation of clozapine treatment are discussed above. (See <a class="local">'Cardiac disease'</a> above and <a class="local">'Cardiovascular'</a> above.)</p><p class="headingAnchor" id="H680708802"><span class="h2">QTc interval prolongation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> causes dose-dependent prolongation of the QT interval on electrocardiogram (ECG) similar in magnitude to <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> [<a href="#rid29">29-32</a>]. QT prolongation increases the risk of torsade de pointes and potentially lethal arrhythmias. Clozapine should be avoided in patients with congenital long QT syndrome; labeling cautions against use in persistent corrected QT interval (QTc) &gt;500 ms on ECG [<a href="#rid33">33</a>]. Higher risk clinical scenarios such as patients with known heart disease, treatment-emergent increase of QTc interval &gt;60 ms from baseline, or co-administration of high-risk medications, may warrant cardiology consultation  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 1</a>). (See <a class="local">'QTc prolongation'</a> above and  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Risk factors for drug-induced long QT syndrome'</a>.)</p><p class="headingAnchor" id="H3282054088"><span class="h2">Pulmonary embolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> has been associated with an increased risk of venous thromboembolic events including pulmonary embolism leading to death [<a href="#rid34">34-40</a>]. Of the published cases with a known outcome, the mortality rate of a clotting complication while on clozapine was 44 percent [<a href="#rid41">41</a>].</p><p>Risk factors for thromboembolic disease in the general population include:</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic factors (mainly the factor V Leiden mutation or a high concentration of factor VIII)</p><p class="bulletIndent1"><span class="glyph">●</span>Recent immobilization</p><p class="bulletIndent1"><span class="glyph">●</span>Recent surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy or the postpartum state</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity</p><p></p><p>Clinicians starting patients on <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> should advise recipients to remain physically active.</p><p>Although prophylactic use to prevent clozapine-associated venous thrombosis of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and statins has not been studied in patients receiving <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, aspirin has been shown to reduce the risk of venous thromboembolism in patients undergoing orthopedic surgery [<a href="#rid42">42</a>], and statins have been shown to reduce venous thromboembolism among individuals receiving chemotherapy for cancer [<a href="#rid43">43</a>]. The routine use of these agents among individuals without contraindications may reduce risk of venous thromboembolism. (See  <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration"</a> and  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer"</a>.)</p><p class="headingAnchor" id="H663666784"><span class="h2">Weight gain</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> can cause significant weight gain [<a href="#rid44">44-48</a>]. The average weight gain in a 10-year cohort study of clozapine was 30 pounds [<a href="#rid44">44</a>]. While most weight gain occurs during the first 6 to 12 months, some patients continue to gain weight without reaching a plateau [<a href="#rid46">46</a>]. Weight should be routinely monitored and behavioral interventions recommended if patients gain weight on clozapine. <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> has been used to blunt antipsychotic-induced weight gain and improve insulin sensitivity [<a href="#rid49">49</a>]. The benefits of added metformin, however, are lost when it is discontinued [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Metabolic dysregulation'</a> and  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Endocrinologic and metabolic side effects'</a>.)</p><p class="headingAnchor" id="H4289532349"><span class="h2">Insulin resistance and diabetes mellitus</span><span class="headingEndMark"> — </span>Of 96 patients with chronic schizophrenia treated with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> and followed for up to 10 years, 34 percent developed diabetes mellitus [<a href="#rid44">44</a>]. The progressive increases in obesity, diabetes, elevated triglycerides, and hypertension in their population resulted in substantially increased cardiovascular risk. The insulin resistance from clozapine treatment is at least in part independent from clozapine-induced weight gain [<a href="#rid51">51</a>]. Screening for diabetes at six-month intervals or more frequently (ie, fasting blood sugar or HbA1c) should be done. (See  <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">"Screening for type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H999612832"><span class="h2">Seizures</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> is associated with a dose-dependent seizure risk at a rate higher than that seen with most other antipsychotic drugs [<a href="#rid52">52,53</a>]. In a review of 1418 patients treated with clozapine, the cumulative seizure risk was estimated to be 10 percent after 3.8 years of treatment [<a href="#rid54">54</a>]. Higher doses of clozapine were associated with a greater rate of seizures:</p><p class="bulletIndent1"><span class="glyph">●</span>600 mg/day or more – 4.4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>300 to 600 mg/day – 2.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>300 mg/day or less – 1.0 percent</p><p></p><p>In a review of 101 patients experiencing a seizure while receiving <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, the most frequently described type of seizure was tonic-clonic; myoclonic/atonic seizures comprise approximately one-quarter of reported seizures [<a href="#rid55">55</a>]. The mean clozapine dose in the cohort was less than 600 mg per day. (See <a class="local">'Seizures'</a> above.)</p><p class="headingAnchor" id="H147798348"><span class="h2">Excessive salivation</span><span class="headingEndMark"> — </span>Clozapine-induced hypersalivation is a common side effect that can be treatment-limiting as patients are unable to tolerate incessant drooling that is stigmatizing during the day and hinders sleeping at night. It often occurs at low doses [<a href="#rid56">56</a>] and can worsen during sleep. Its mechanism is thought to be due to a disturbance of deglutition and not merely an increase in salivary flow rate [<a href="#rid57">57</a>]. Hypersalivation may be a risk factor for aspiration pneumonia, which has been observed in clozapine-treated patients [<a href="#rid58">58</a>].</p><p>A reduction in <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> dose can be tried to limit salivation, but this step alone is often inadequate. Among treatment options, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a> at a dose of 2 to 4 mg given at night is a good initial choice. A randomized trial compared glycopyrrolate with biperiden [<a href="#rid59">59</a>]. While both were associated with a reduced rate of drooling, a larger decrease was seen in the group taking glycopyrrolate. Glycopyrrolate does not penetrate the blood-brain barrier, thus avoiding central anticholinergic effects such as impairment of memory. However, it adds to clozapine’s already significant intrinsic peripheral anticholinergic burden. (See <a class="local">'Gastrointestinal hypomotility'</a> below.)</p><p>Other treatment approaches, based on case reports or case series, include the use of sugarless chewing gum to increase the rate of swallowing, anticholinergic agents (eg, 5 to 15 mg/day of <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">trihexyphenidyl</a>), topical agents (eg, sublingual <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> or <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> spray) or alpha-2 agonists (eg, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>). In refractory cases, botulinum toxin injections into the salivary glands can be effective if this treatment can be arranged.</p><p class="headingAnchor" id="H2740115151"><span class="h2">Urinary incontinence</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> appears to be associated with an increased incidence of urinary incontinence. The potent anti-alpha-adrenergic effects of clozapine, which relax the bladder-neck sphincter, are hypothesized to contribute to the incontinence. An open trial of 16 patients suggested that <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a>, an alpha-adrenergic agonist, may be highly effective in treating clozapine induced urinary incontinence, supporting the hypothesis [<a href="#rid60">60</a>]. A dose of 25 mg ephedrine at night or 25 mg twice daily is often sufficient to treat urinary incontinence. Ephedrine may be difficult to obtain due to concerns about diversion to the synthesis of methamphetamines; <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">pseudoephedrine</a> may be a reasonable substitute at doses of 30 to 60 mg twice daily.</p><p class="headingAnchor" id="H2889684357"><span class="h2">Gastrointestinal hypomotility</span><span class="headingEndMark"> — </span>Gastrointestinal hypomotility likely due to the anticholinergic properties of the medication [<a href="#rid61">61</a>] may lead to constipation. Constipation has been reported in approximately 14 percent of patients treated with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> [<a href="#rid62">62</a>]. Delayed diagnosis and treatment may result in fecal impaction, megacolon, intestinal obstruction, perforation, ulceration, or necrosis [<a href="#rid63">63</a>].</p><p>Severe constipation, culminating in adynamic ileus, can be fatal. In a report of 102 cases of life-threatening gastrointestinal hypomotility suspected to be caused by <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, considerable morbidity was seen (largely due to bowel resection) along with a mortality rate of 27.5 percent [<a href="#rid64">64</a>]. Probable risk factors included:</p><p class="bulletIndent1"><span class="glyph">●</span>Recent initiation of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a></p><p class="bulletIndent1"><span class="glyph">●</span>High <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> doses or serum levels</p><p class="bulletIndent1"><span class="glyph">●</span>Use of other drugs with anticholinergic activity</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid medical illness</p><p></p><p>In a retrospective analysis of diagnostic and pharmacy data on 26,720 inpatients with schizophrenia over an 11-year period, 123 cases of ileus were observed [<a href="#rid65">65</a>]. Female sex and <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> treatment were associated with an increased risk of ileus. Nine of the ileus cases (7.3 percent) had a fatal course, with clozapine treatment and anticholinergic use associated with lethality. The onset of ileus occurred on average more than three years after the first prescription of the offending drug. In a comparative effectiveness study of 3123 patients who initiated clozapine, intestinal obstruction emerged as a clinically significant adverse effect, seen in a greater proportion of clozapine patients compared with patients on a standard antipsychotic (0.9 versus 0.3 percent; hazard ratio 2.50, 95% CI 0.97-6.44) [<a href="#rid66">66</a>].</p><p>Patients receiving psychotropics associated with significant anticholinergic properties should undergo proper clinical monitoring and interventions in order to minimize the burden of constipation and the risk of ileus. Patients can be encouraged to eat a diet high in fiber, drink plenty of fluids, and exercise. (See  <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">"Management of chronic constipation in adults"</a>.)</p><p class="headingAnchor" id="H3588473957"><span class="h2">Sedation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> can cause significant sedation, particularly during the initiation of treatment. Tolerability of the sedating effect can be enhanced by gradually titrating to a therapeutic dose. Some clinicians add stimulants or stimulant-like drugs if patients continue to experience sedation. However, two small randomized trials in patients with clozapine-induced sedation found no benefit from <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> (200 to 300 mg/day) on measures of fatigue or wakefulness [<a href="#rid67">67,68</a>].</p><p class="headingAnchor" id="H1546252432"><span class="h2">Teratogenic and neonatal risks</span><span class="headingEndMark"> — </span>Although no definitive association has been found between use of antipsychotic medications during pregnancy and an increased risk of congenital anomaly or other adverse outcomes, there is a paucity of information, with a lack of large, well-designed, prospective studies. Second-generation antipsychotics cross the placenta [<a href="#rid69">69</a>]. Case reports have demonstrated concentrations of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in breast milk [<a href="#rid70">70</a>]. The American College of Obstetricians and Gynecologists does not recommend the routine use of second-generation antipsychotics during pregnancy; however, assessment of risk-benefit may indicate that such use is appropriate [<a href="#rid71">71</a>]. The American Academy of Pediatrics has classified clozapine as a drug whose effect on the nursing infant is unknown but may be of concern [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Second-generation'</a>.)</p><p class="headingAnchor" id="H2252472414"><span class="h2">Mortality risk</span><span class="headingEndMark"> — </span>The US Food and Drug Administration has reported that the use of first- and second-generation antipsychotic medications for the treatment of behavioral symptoms in older adult patients with dementia is associated with increased mortality [<a href="#rid73">73,74</a>]. (See  <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia", section on 'Mortality risk'</a>.)</p><p class="headingAnchor" id="H1191655502"><span class="h2">Movement disorders</span><span class="headingEndMark"> — </span>Compared with other antipsychotics, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> has a reduced risk of causing tardive dyskinesia or extrapyramidal movement disorders including akathisia. However, patients can still develop these movement disorders and need to be monitored for their development (eg, standardized motor exam with the Abnormal Involuntary Movement Scale every six months)  (<a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">form 1</a>). Despite clozapine’s weak affinity for the dopamine receptor, the neuroleptic malignant syndrome can develop [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/4908.html" rel="external">"Tardive dyskinesia: Prevention, treatment, and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome"</a>.)</p><p class="headingAnchor" id="H1376967121"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117525.html" rel="external">"Society guideline links: Psychotic disorders"</a>.)</p><p class="headingAnchor" id="H350566201"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– Primary indications for <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> include schizophrenia or schizoaffective disorder partially or fully resistant to treatment with other antipsychotic drugs, or schizophrenia/schizoaffective accompanied by persistent suicidal or self-injurious behavior. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment assessment </strong>–<strong> </strong>Prior to beginning <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, we do the following baseline evaluation (see <a class="local">'Pretreatment assessment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>General and cardiovascular health status, vital signs, weight, height, body mass index</p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count (absolute neutrophil count [ANC] must be ≥1500/microL to initiate <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Check for therapeutic drug levels of anticonvulsant medications</p><p class="bulletIndent2"><span class="glyph">•</span>Fasting blood sugar or HbA1c, fasting lipids (non-high-density lipoprotein cholesterol if nonfasting)</p><p class="bulletIndent2"><span class="glyph">•</span>Electrocardiogram (ECG)</p><p class="bulletIndent2"><span class="glyph">•</span>Baseline Abnormal Involuntary Movement Scale test</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy test in women of childbearing age</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>–<strong> </strong>For patients initially starting <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in nonurgent situations, we prefer a slow titration. As an example, we suggest 12.5 to 25 mg once daily at bedtime for three to four days, then 25 to 50 mg once daily at bedtime for three to four days. We increase by 25 mg twice weekly. In urgent situations (active aggression/violence or self-injury/suicide) we double the titration rate above.</p><p></p><p class="bulletIndent1">The initial target dose for healthy, young adults is 300 mg/day. A maintenance dose of 300 to 600 mg/day is usually required for efficacy. Doses higher than 900 mg/day are not recommended. We are cautious with older adults (&gt;65 years) and in individuals with comorbid medical or cardiac disease. Typical maintenance dose may be as low as 100 to 150 mg/day. We titrate slowly in these individuals to avoid adverse effects. We check plasma levels once target dose is reached or earlier (after 100 mg are reached). (See <a class="local">'Administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – For all patients taking <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in the United States, the US Food and Drug Administration requires regular monitoring and registry reporting of neutrophil counts. Patients taking clozapine should receive routine weekly-to-monthly monitoring and maintain an ANC ≥1500/microL (≥1000/microL for individuals with Duffy-null associated neutrophil count. Lower ANC levels require more frequent monitoring, and possible interruption of clozapine and/or reevaluation of its use. Monitoring frequency is as follows (see <a class="local">'Monitoring'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weekly during the first six months of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> administration</p><p class="bulletIndent2"><span class="glyph">•</span>Every other week for the second six months</p><p class="bulletIndent2"><span class="glyph">•</span>Every four weeks after one year, for the duration of treatment</p><p></p><p class="bulletIndent1">If neutropenia develops during treatment, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> we either monitored more frequently, stopped the medication temporarily, or discontinued the medication, based on the severity of neutropenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> (see <a class="local">'Adverse effects'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neutropenia/agranulocytosis</strong> – Clozapine-induced agranulocytosis occurs at a rate of approximately 0.8 percent. Leukopenia occurs in approximately 3 percent of cases. The peak risks for both occurred early in treatment, between 6 to 18 weeks from initiation. (See <a class="local">'Neutropenia/agranulocytosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiovascular effects</strong> – Clozaril is associated with early myocarditis that can lead to the development of cardiomyopathy. Additionally, it can cause a dose dependent QTc prolongation. We obtain an ECG prior to starting <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>; we repeat the ECG once steady state is obtained. (See <a class="local">'Myocarditis/cardiomyopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Insulin resistance, weight gain, metabolic dysregulation</strong> – <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> can cause insulin resistance, metabolic dysregulation and weight gain. While most weight gain occurs during the first 6 to 12 months, some patients continue to gain weight without reaching a plateau. We monitor metabolic parameters at regular intervals. (See <a class="local">'Insulin resistance and diabetes mellitus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizures </strong>– <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> is associated with a dose-dependent seizure risk at a rate higher than that seen with most other antipsychotic drugs (See <a class="local">'Seizures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other effects</strong> – Treatment with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> can cause constipation, sedation, sialorrhea, incontinence, pulmonary embolism. Treatment with antipsychotics including clozapine is associated with increased mortality in individuals with dementia. (See <a class="local">'Adverse effects'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Clozapine REMS Program https://newclozapinerems.com/home.</li><li><a class="nounderline abstract_t">Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188:255.</a></li><li class="breakAll">Prescriber. Clozapine REMS. Available at: https://www.newclozapinerems.com/Public/home/Prescriber (Accessed on June 15, 2022).</li><li><a class="nounderline abstract_t">Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172:1703.</a></li><li><a class="nounderline abstract_t">Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24:161.</a></li><li><a class="nounderline abstract_t">Facciolà G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998; 20:628.</a></li><li><a class="nounderline abstract_t">Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995; 28:26.</a></li><li><a class="nounderline abstract_t">Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16:368.</a></li><li><a class="nounderline abstract_t">Müller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988; 2:1500.</a></li><li><a class="nounderline abstract_t">Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry 1993; 26:262.</a></li><li><a class="nounderline abstract_t">Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28:99.</a></li><li><a class="nounderline abstract_t">VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153:1579.</a></li><li><a class="nounderline abstract_t">Northwood K, Pearson E, Arnautovska U, et al. Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis. Br J Psychiatry 2023; 222:241.</a></li><li><a class="nounderline abstract_t">Wagner E, Kane JM, Correll CU, et al. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophr Bull 2020; 46:1459.</a></li><li><a class="nounderline abstract_t">Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 1997; 42:132.</a></li><li class="breakAll">Institute for Safe Medication Practices Safety Alert. Potential for severe cardiovascular effects when restarting clozapine. ISMP 2022; 27: 1, 1-3.</li><li><a class="nounderline abstract_t">Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47:52.</a></li><li><a class="nounderline abstract_t">Nielsen H. Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis. J Intern Med 1993; 234:529.</a></li><li><a class="nounderline abstract_t">Lamberti JS, Bellnier TJ, Schwarzkopf SB, Schneider E. Filgrastim treatment of three patients with clozapine-induced agranulocytosis. J Clin Psychiatry 1995; 56:256.</a></li><li class="breakAll">U.S. Food and Drug Administration. Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency: Guidance for Industry and Health Care Professionals. March, 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-certain-rems-requirements-during-covid-19-public-health-emergency-guidance-industry-and (Accessed on March 26, 2020).</li><li><a class="nounderline abstract_t">Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci 2020; 45:200061.</a></li><li><a class="nounderline abstract_t">Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 2018; 138:101.</a></li><li><a class="nounderline abstract_t">Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45:458.</a></li><li><a class="nounderline abstract_t">Handley SA, Every-Palmer S, Ismail A, Flanagan RJ. Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992-2017. Br J Psychiatry 2022; :1.</a></li><li><a class="nounderline abstract_t">Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999; 175:576.</a></li><li><a class="nounderline abstract_t">Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59 Suppl 3:3.</a></li><li><a class="nounderline abstract_t">Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30:47.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019758s080lbl.pdf (Accessed on January 17, 2017).</li><li><a class="nounderline abstract_t">Xiang YT, Chiu HF, Ungvari GS, et al. QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009. Hum Psychopharmacol 2015; 30:94.</a></li><li><a class="nounderline abstract_t">Lin CH, Chen MC, Wang SY, Lin CY. Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. J Formos Med Assoc 2004; 103:437.</a></li><li><a class="nounderline abstract_t">Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One 2013; 8:e81208.</a></li><li class="breakAll">American Psychiatric Association Resource Documents (2018) https://www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/resource_documents/Resource-Document-2018-QTc-Prolongation-and-Psychotropic-Med.pdf (Accessed on May 21, 2021).</li><li class="breakAll">Clozaril (clozapine) tablet US prescribing information https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=90876802-0e3a-44c9-9ff7-1754dfbe736a&amp;type=pdf (Accessed on May 21, 2021).</li><li><a class="nounderline abstract_t">Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8:671.</a></li><li><a class="nounderline abstract_t">Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355:1155.</a></li><li><a class="nounderline abstract_t">Kortepeter C, Chen M, Knudsen JF, et al. Clozapine and venous thromboembolism. Am J Psychiatry 2002; 159:876.</a></li><li><a class="nounderline abstract_t">Ihde-Scholl T, Rolli ML, Jefferson JW. Clozapine and pulmonary embolus. Am J Psychiatry 2001; 158:499.</a></li><li><a class="nounderline abstract_t">Farah RE, Makhoul NM, Farah RE, Shai MD. Fatal venous thromboembolism associated with antipsychotic therapy. Ann Pharmacother 2004; 38:1435.</a></li><li><a class="nounderline abstract_t">Yang TY, Chung KJ, Huang TL, Kung CT. Massive pulmonary embolism in a young patient on clozapine therapy. J Emerg Med 2004; 27:27.</a></li><li><a class="nounderline abstract_t">Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165:2677.</a></li><li><a class="nounderline abstract_t">Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 2008; 65:1825.</a></li><li><a class="nounderline abstract_t">Marsland D, Mears SC, Kates SL. Venous thromboembolic prophylaxis for hip fractures. Osteoporos Int 2010; 21:S593.</a></li><li><a class="nounderline abstract_t">Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123:60.</a></li><li><a class="nounderline abstract_t">Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66:1116.</a></li><li><a class="nounderline abstract_t">Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149:689.</a></li><li><a class="nounderline abstract_t">Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55 Suppl B:157.</a></li><li><a class="nounderline abstract_t">Bai YM, Lin CC, Chen JY, et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163:1276.</a></li><li><a class="nounderline abstract_t">Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009; 70:1041.</a></li><li><a class="nounderline abstract_t">Carrizo E, Fernández V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009; 113:19.</a></li><li><a class="nounderline abstract_t">Chen CH, Huang MC, Kao CF, et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013; 74:e424.</a></li><li><a class="nounderline abstract_t">Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62:19.</a></li><li><a class="nounderline abstract_t">Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44:2247.</a></li><li><a class="nounderline abstract_t">Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007; 62:345.</a></li><li><a class="nounderline abstract_t">Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41:369.</a></li><li><a class="nounderline abstract_t">Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 2007; 52:457.</a></li><li><a class="nounderline abstract_t">Freudenreich O. Drug-induced sialorrhea. Drugs Today (Barc) 2005; 41:411.</a></li><li><a class="nounderline abstract_t">Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 1996; 40:1132.</a></li><li><a class="nounderline abstract_t">Gurrera RJ, Parlee AC, Perry NL. Aspiration Pneumonia: An Underappreciated Risk of Clozapine Treatment. J Clin Psychopharmacol 2016; 36:174.</a></li><li><a class="nounderline abstract_t">Liang CS, Ho PS, Shen LJ, et al. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res 2010; 119:138.</a></li><li><a class="nounderline abstract_t">Fuller MA, Borovicka MC, Jaskiw GE, et al. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996; 57:514.</a></li><li><a class="nounderline abstract_t">Hayes G, Gibler B. Clozapine-induced constipation. Am J Psychiatry 1995; 152:298.</a></li><li><a class="nounderline abstract_t">Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24:381.</a></li><li class="breakAll">Clozapine package insert. HLS Therapeutics, Rosemont, PA. 2022.</li><li><a class="nounderline abstract_t">Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008; 69:759.</a></li><li><a class="nounderline abstract_t">Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull 2012; 38:592.</a></li><li><a class="nounderline abstract_t">Stroup TS, Gerhard T, Crystal S, et al. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. Am J Psychiatry 2016; 173:166.</a></li><li><a class="nounderline abstract_t">Freudenreich O, Henderson DC, Macklin EA, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry 2009; 70:1674.</a></li><li><a class="nounderline abstract_t">Sevy S, Rosenthal MH, Alvir J, et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 2005; 66:839.</a></li><li><a class="nounderline abstract_t">Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214.</a></li><li><a class="nounderline abstract_t">Barnas C, Bergant A, Hummer M, et al. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994; 151:945.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. Reaffirmed Obstet Gynecol 2018; 131:185. Reaffirmed 2020.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.</a></li><li><a class="nounderline abstract_t">Devanand DP, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46:854.</a></li><li><a class="nounderline abstract_t">Dev VJ, Rosenberg T, Krupp P. Agranulocytosis and clozapine. BMJ 1994; 309:54.</a></li><li><a class="nounderline abstract_t">Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69:1157.</a></li></ol></div><div id="topicVersionRevision">Topic 14772 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://newclozapinerems.com/home" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clozapine REMS Program https://newclozapinerems.com/home.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507968" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Rechallenge with clozapine following leucopenia or neutropenia during previous therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507968" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Rechallenge with clozapine following leucopenia or neutropenia during previous therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967975" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Modern antipsychotic drugs: a critical overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8453823" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pharmacokinetics and pharmacodynamics of clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9853978" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7746842" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Carbamazepine-induced changes in plasma levels of neuroleptics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7974626" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2904624" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neuroleptic malignant syndrome after clozapine plus carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127933" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12670127" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Interactions between the cytochrome P450 system and the second-generation antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8942454" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36994656" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32421188" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9209730" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9209730" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8925346" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7693847" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539786" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Filgrastim treatment of three patients with clozapine-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539786" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Filgrastim treatment of three patients with clozapine-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32242646" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Consensus statement on the use of clozapine during the COVID-19 pandemic</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29786829" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Meta-analysis examining the epidemiology of clozapine-associated neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21524186" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35164895" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10789357" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541331" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17194170" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17194170" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25611192" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15278188" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24278396" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24278396" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24278396" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9345668" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mortality in current and former users of clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791380" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association of venous thromboembolism and clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986154" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clozapine and venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11230003" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clozapine and pulmonary embolus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280515" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fatal venous thromboembolism associated with antipsychotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15219300" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Massive pulmonary embolism in a young patient on clozapine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344428" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18796423" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evaluating the association between clozapine and venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057999" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Venous thromboembolic prophylaxis for hip fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20102993" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Statins decrease the occurrence of venous thromboembolism in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16187768" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349460" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Weight gain among schizophrenic patients treated with clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7961563" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clozapine and weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16816235" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association of initial antipsychotic response to clozapine and long-term weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19653979" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19515536" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759461" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630069" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7991106" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clozapine-related seizures: experience with 5,629 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223086" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006003" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clozapine-related seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17688010" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clozapine-induced seizures: recognition and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110348" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Drug-induced sialorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8931916" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The effect of clozapine on saliva flow rate: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26848787" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Aspiration Pneumonia: An Underappreciated Risk of Clozapine Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299191" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8968299" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clozapine-induced urinary incontinence: incidence and treatment with ephedrine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840373" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clozapine-induced constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9718630" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of the adverse effects of clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9718630" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Management of the adverse effects of clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452342" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21112965" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk factors for ileus in patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26541815" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19689921" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16013898" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671284" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8185013" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533352" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Transfer of drugs and other chemicals into human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2667504" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044077" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Agranulocytosis and clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18572981" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
